Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes.
To prevent hyperinsulinemia, which may cause atherosclerosis, thiazolidinediones (TZDs), also known as insulin sensitizers, are often added to the therapeutic regimen of patients with type 2 diabetes who are receiving insulin. The combination of insulin with pioglitazone, a TZD, reduces glycoated hemoglobin (HbA(1c)) by 0.6%-2.1%. The higher the HbA(1c) baseline the larger the therapeutic reduction of HbA(1c). This combination therapy has been shown to be beneficial even in lean Japanese patients with diabetes. It should be noted that such combination therapy is much more useful when the main clinical aim is lowering not postprandial, but fasting and nocturnal glycemia. The glycemic-lowering effects of pioglitazone alone occur slowly, whereas the addition of insulin to pioglitazone often shows a dramatic glucose-lowering effect. Thus, such combination therapy increases the possibility of frequent hypoglycemia within 1 to 2 months of combining the drugs. Severe hypoglycemia in patients using this therapy is rare. Patients treated with combination therapy who show a predominant reduction of glycemia often have severe edema; in 10%-20% of patients, combination therapy leads to drug-related congestive heart failure (CHF). However, this phenomenon is usually weakened if low doses of pioglitazone which are added to insulin therapy (ie, 15 mg/day or even 7.5 mg/day for women). It is well known that pioglitazone has an anti-atherosclerotic effect, although it is unclear if hyperinsulinemia induces atherogenic changes, either directly or indirectly, by the promotion of obesity. Until now, we have not confirmed whether the anti-atherosclerotic effects of pioglitazone exceed the supposed disadvantageous action of insulin when used in combination therapy. The addition of pioglitazone tends to reduce daily insulin dosages, but study findings have not been consistent. Improvement of lipid profiles has also been weak with this combination therapy. Long-term trials are needed before any conclusions can be reached concerning atherogenic effects of treatment for type 2 diabetes. Combination therapy of even small doses of pioglitazone with insulin should be primarily used for patients who achieve insufficient reduction in glycemia with insulin monotherapy.
Yamanouchi
Toshikazu
T
Kita-Tokyo-Jueien/Department of Internal Medicine, Teikyo University, Tokyo, Japan. yama@med.teikyo-u.ac.jp
D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007328:Insulin / Q000009:adverse effects / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D000077205:Pioglitazone; D045162:Thiazolidinediones / Q000009:adverse effects / Q000627:therapeutic use*
D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D008055:Lipids; D000077205:Pioglitazone; D045162:Thiazolidinediones
CMAJ. 2009 Jan 6;180(1):32-9
19073651
J Clin Endocrinol Metab. 2001 Jul;86(7):3257-65
11443198
Diabetes Care. 1998 Sep;21(9):1470-4
9727893
Drug Saf. 2004;27(12):841-56
15366973
Am J Physiol Endocrinol Metab. 2009 Sep;297(3):E568-77
19491294
JAMA. 2008 Apr 2;299(13):1561-73
18378631
Diabetes Care. 1995 Aug;18(8):1156-9
7587851
Diabetologia. 1981 Sep;21(3):165-71
7028550
Lancet. 2008 Mar 29;371(9618):1073-84
18374840
Diabetes Obes Metab. 2006 Mar;8(2):164-74
16448520
Diabetes Care. 2005 Jul;28(7):1547-54
15983299
Clin Ther. 2004 May;26(5):680-93
15220012
Diabetes Care. 2007 Aug;30(8):2148-53
17536074
Diabetes Care. 2003 Jun;26(6):1902-12
12766131
Diabetes. 2001 May;50(5):1158-65
11334421
Diabetes Care. 2004 Jan;27(1):17-20
14693960
Diabetes Care. 2003 Nov;26(11):2983-9
14578227
Diabetes Care. 2002 Nov;25(11):2058-64
12401757
J Am Coll Cardiol. 2005 Jun 21;45(12):1925-31
15963388
Diabetes Care. 2009 Jan;32(1):193-203
18945920
Diabetes Obes Metab. 2004 Mar;6(2):133-56
14746579
Diabetes Obes Metab. 2009 May;11(5):464-71
19422402
Metab Syndr Relat Disord. 2006 Fall;4(3):179-84
18370736
N Engl J Med. 2006 Dec 7;355(23):2427-43
17145742
Clin Ther. 2005 May;27(5):554-67
15978304
Int J Obes Relat Metab Disord. 2003 Feb;27(2):147-61
12586994
Annu Rev Biochem. 2001;70:341-67
11395411
J Clin Endocrinol Metab. 2006 Sep;91(9):3349-54
16608888
Diabet Med. 2008 Oct;25(10):1151-6
19046192
Lancet. 2008 May 24;371(9626):1725-6
18502278
Diabetes. 1988 Aug;37(8):1020-4
3292322
Clin Ther. 2005 Sep;27(9):1432-43
16291416
Lancet. 2005 Oct 8;366(9493):1279-89
16214598
Diabet Med. 2005 Aug;22(8):980-5
16026361
Ann Pharmacother. 2004 May;38(5):817-20
15039476
Diabetes Care. 2003 Sep;26(9):2700
12941750
Lancet. 2007 Sep 29;370(9593):1129-36
17905165
Diabetes Care. 2001 Jul;24(7):1226-32
11423507
Endocr Rev. 2002 Oct;23(5):599-622
12372842
Clin Sci (Lond). 2001 Sep;101(3):227-33
11524039
J Clin Endocrinol Metab. 2003 Aug;88(8):3993-6
12915698
Am J Hypertens. 1996 Aug;9(8):746-52
8862220
N Engl J Med. 2004 Sep 9;351(11):1106-18
15356308
N Engl J Med. 1998 Mar 26;338(13):861-6
9516220
J Clin Invest. 2004 Nov;114(9):1187-95
15520847
N Engl J Med. 2008 Jun 12;358(24):2545-59
18539917
Diabetes Care. 2004 Jun;27(6):1349-57
15161787
Ann Med. 2002;34(3):217-24
12173692
Int J Clin Pract. 2002 May;56(4):251-7
12074206
Diabetes Care. 2002 May;25(5):883-8
11978685
Diabetes Obes Metab. 2007 Jul;9(4):512-20
17587394
Diabetes Care. 2001 Apr;24(4):710-9
11315836
Diabetes Care. 2005 Feb;28(2):260-5
15677776
Mayo Clin Proc. 2003 Sep;78(9):1088-91
12962163
Diabetes. 2008 May;57(5):1349-54
18299315
Diabetes. 1997 Mar;46(3):433-9
9032099
J Clin Endocrinol Metab. 2002 Jun;87(6):2784-91
12050251
Expert Opin Pharmacother. 2006 Mar;7(4):463-76
16503818
Circ Res. 2008 Feb 15;102(3):283-94
18276926
Diabetes Care. 1998 Sep;21(9):1455-61
9727891
Clin Ther. 2001 Nov;23(11):1792-823; discussion 1791
11768834
J Clin Endocrinol Metab. 2007 Apr;92(4):1256-62
17244785
Diabetes. 2001 May;50(5):1166-70
11334422
Pharmacotherapy. 2002 Jul;22(7):924-9
12126225
Nat Med. 2007 Dec;13(12):1496-503
18059282
Diabetes. 2002 Mar;51(3):718-23
11872672
Diabetes Care. 2002 Oct;25(10):1691-8
12351463
Can J Cardiol. 2001 Aug;17(8):859-65
11521128
Diabetes Care. 2003 Nov;26(11):3148-52
14578253
Diabetes Care. 2008 Jan;31(1):121-7
17909084
Atherosclerosis. 2001 Sep;158(1):113-9
11500181
Diabetes. 1996 Aug;45(8):1044-50
8690150
Diabetes Care. 2009 Jan;32(1):187-92
19092168